Rose Medical Center, Denver
Antiretroviral treatment decisions based on toxicity/resistance/convenience
Published in Law and Health Weekly, November 27th, 2004
"Several dual nucleoside reverse transcriptase inhibitor (NRTI) combinations provide efficacy when combined with a 3rd agent. However, there are a number of issues with current NRTI and nucleotide reverse transcriptase inhibitor (NtRTI) combinations that often lead to treatment failure and limited treatment options.
"These issues include suboptimal potency, drug interactions, toxicities, tolerability issues, and selection of resistance mutations that confer cross-resistance," scientists in the United States report.
"Options for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Aastrom Biosciences, Inc.
Diabetic limb ischemia clinical trial agreement signed - Decision Resources
Study shows 16% increase in 2003-2004 HMO Medicare enrollment in 6 states - Facing Our Risk of Cancer Empowered
Genetic counselors and advocacy group develop genetic discrimination brochure - Genmab
Antibodies with activity against non-Hodgkin lymphomas characterized - INSERM U379, Marseille
BRCA1/2 tests available, but ethics, economics restrain use in France - Legal Issues
Washington man sentenced for stealing cancer patient's identity - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
